.Attribute Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after an average consequence of 11 months, people with metastatic intestinal lumps who obtained biomarker-matched treatments based upon spreading lump DNA profiling presented a greater medical perk than those receiving unparalleled therapy.